Lite Strategy Business Summary

Lite Strategy, Inc. (NASDAQ: LITS) operates a dual-segment business model centered on active digital asset treasury management and the monetization of legacy pharmaceutical assets. The company generates revenue primarily through active capital market operations, such as its covered call options program on its Litecoin (LTC) holdings, which produced approximately $600,000 in gross premiums in Q2 2026. Its primary business segments include the Digital Asset Treasury, where it serves as the first U.S. public company to adopt Litecoin as a primary reserve asset (holding over 929,000 LTC), and a Pharmaceutical R&D arm focused on out-licensing or selling clinical-stage oncology and non-oncology therapies like voruciclib and zandelisib. LITS competes directly with other digital asset treasury pioneers such as MicroStrategy (MSTR), Semler Scientific (SMLR), and Metaplanet, positioning itself as a unique institutional vehicle that offers active yield generation and LTC-specific exposure, distinguishing it from passive spot ETFs. The leadership team is spearheaded by Justin "Jay" File, who serves as the permanent CEO, CFO, and Secretary, bringing extensive experience from his tenure as the financial lead during the company’s transition from MEI Pharma. The strategic pivot to a Litecoin-centric model is supported by a high-pedigree board of directors, most notably Charlie Lee, the creator of Litecoin and former Director of Engineering at Coinbase, and Joshua Riezman, the U.S. Chief Strategy Officer at GSR. Other key board members include Independent Chairperson Frederick W. Driscoll and Dr. Nick Glover. The company maintains a strategic partnership with GSR to guide its treasury execution and has attracted institutional interest from major investors such as Citadel Advisors LLC, reflecting its evolution from a clinical-stage biotech firm into a specialized digital asset powerhouse.